Biomerica Inc (BMRA)vsBoston Scientific Corp (BSX)
BMRA
Biomerica Inc
$1.62
+5.88%
HEALTHCARE · Cap: $4.94M
BSX
Boston Scientific Corp
$47.75
-2.75%
HEALTHCARE · Cap: $71.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 485132% more annual revenue ($21.00B vs $4.33M). BSX leads profitability with a 17.5% profit margin vs -96.5%. BSX earns a higher WallStSmart Score of 72/100 (B).
BMRA
Avoid26
out of 100
Grade: F
BSX
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMRA.
Margin of Safety
-22.3%
Fair Value
$39.03
Current Price
$47.75
$8.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Price/Book, Debt/Equity.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Price/Book. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while BSX is a mature play — different risk/reward profiles.
BSX carries more volatility with a beta of 0.57 — expect wider price swings.
BSX is growing revenue faster at 7.5% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 26/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
Visit Website →Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?